Add listing
    0
    Add listing

    GABAb PAM for Substance Abuse Disorders

    Indicaton

    Milestone: IND enabling expected 2024

    Our partner, Indivior, has licensed worldwide rights to our GABAB PAM program and is responsible for all development, manufacture and commercialization of any selected GABAB PAM drug candidates.

    Therapeutic indications
    Type of product
    Table
    • Phase
      Discovery
    • Partnering status
      Partnered
    • Partner
      Indivior PLC

    You may also be interested in